It's hard to argue with the statement that no ischemia is probably better than some ischemia, but at what cost?
Rapid genetic testing model found feasible for patients with prostate cancer
"In our sample, nearly 10% of patients [with prostate cancer] had a gene variant that made them eligible for effective new therapies, with faster results than traditional referral for genetic testing and counseling,” said Maria I. Carlo, MD.
Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer
Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
Study suggests available deep learning software does not enhance assessment of bi-parametric prostate MRI
The deep learning software also showed no difference in the consistency of scoring with the Prostate Imaging-Reporting and Data System (PI-RADS).
Speaking of Urology: ASCO GU 2023 Highlights
Laura Bukavina, MD, and Kyle Rose, MD, discuss some of the notable abstracts from the 2023 ASCO GU conference.
FDA grants full approval to pembrolizumab for MSI-H/dMMR solid tumors, including genitourinary cancers
Prostate cancer, bladder cancer, renal cell carcinoma were among the multitude of tumor types assessed in the analysis supporting the approval.
AI model able to generate high-quality synthetic prostate cancer MRIs
"The improvement in technologies could potentially assist radiation oncologists in making timely decisions,” said Himanshu Arora, PhD.
2 Clarke Drive Cranbury, NJ 08512